Not So Different: A Podcast From The Center For Biosimilars

  • Autor: Vários
  • Narrador: Vários
  • Editor: Podcast
  • Duración: 31:34:48
  • Mas informaciones

Informações:

Sinopsis

"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.

Episodios

  • S6 Ep6: Biosimilars Policy Roundup for March 2023—Podcast Edition

    02/04/2023 Duración: 03min

    Show notes Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy Policy Recommendations for Improving Biosimilar Uptake in Belgium Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies Dr Ivo Abraham Column: The 2022 WHO Biosimilar Guidelines—Loosening the Reins or Changing the Track? Part 2 The Increasing Access to Biosimilars Act of 2023 Introduced to Congress Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar Switching Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns

  • S6 Ep5: How Community Oncologists Can Break Down Biosimilar Adoption Barriers

    19/03/2023 Duración: 13min

    Show notes To listen to our podcast with Cheryl Vaughn, vice president of clinical services at McKesson, discussed how McKesson's Intrafusion service helps manage infusion sites and aids in the administration of complex biologic drugs, including biosimilars, click here.

  • S6 Ep4: Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition

    05/03/2023 Duración: 05min

    Show notes Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years Vizient Report Predicts Over 3% Inflation Rate for Biologics https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars Patients With RA, IBD Trust Spec

  • S6 Ep3: On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars

    26/02/2023 Duración: 13min

    Show notes To learn more about Vizient’s Pharmacy Outlook Report, click here. To read Dr. Dolan’s paper “Opportunities and Challenges in Biosimilar Uptake in Oncology published in The American Journal of Managed Care®, click here. To read Dr. Dolan’s paper “Evolving Practices in Managing Costly Immunotherapy” published in The American Journal of Managed Care®, click here.

  • S6 Ep2: Biosimilars Rheumatology Roundup for January 2023—Podcast Edition

    05/02/2023 Duración: 05min

    Show notes US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita  Canada Approves High-Concentration Humira Biosimilar https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar  Celltrion Submits BLA for Infliximab Biobetter https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter  FDA Accepts BLA for Alvotech Ustekinumab Biosimilar https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar  Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study  China's NMPA Approves Tocilizumab Biosimilar https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar   US Welcomes First Adalimumab Biosimilar, Amjevit

  • S6 Ep1: Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars

    29/01/2023 Duración: 13min

    Show notes: To check out part 1 of this interview series (written Q&A with Samsung Bioepis’ Kyung-Ah Kim), click here. Coming soon, part 3 will be a video interview about the initial market response to ophthalmology biosimilars and how industry leaders can work together to increase uptake. To learn more about the approval of Cimerli, click here. To learn more about ophthalmology biosimilars, click here. To learn more about interchangeability, click here. To learn more about clinical efficacy testing, click here. To learn more about our LinkedIn Live event on ophthalmology biosimilars, you can read more here or watch the full discussion here. To check out the FDA’s overview page on biosimilars, click here. To check out the FDA’s patient-focused biosimilar education materials (English and Spanish versions), click here. To check out the FDA’s biosimilar education materials for health care professionals, click here. For more information on the FDA's biosimilar curriculum, click here. For more information o

  • S5 Ep14: Goodbye 2022—The Top 10 Biosimilars Stories of the Year

    01/01/2023 Duración: 05min

    Top 10 stories of the year: 10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar 9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA 8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023 7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology 6. Report: Biosimilar Competition in Europe 5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options             - For the whole series, click here.  4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira 3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab 2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar 1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid Top 5 podcast episodes of the year: 5. How Health Policy Can Impact Adoption for Adalimumab Biosimilars 4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the Fi

  • S5 Ep13: New Year, New Hurdles: What's in Store for Biosimilars in 2023

    18/12/2022 Duración: 18min

    To read more about adalimumab biosimilars, click here. To read more about ophthalmology biosimilars, click here. To learn more about the Inflation Reduction Act’s impact on biosimilars, click here. To read more about the reauthorization of the Biosimilars User Fee Amendment, click here. To learn more about interchangeability, click here.

  • S5 Ep12: Biosimilars Regulatory Roundup for November 2022—Podcast Edition

    04/12/2022 Duración: 04min

    Show notes Rezvoglar Becomes Second Interchangeable Insulin Biosimilar Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed The European Union Gains Another Ranibizumab Biosimilar Alvotech Snags Australian Approval for Adalimumab Biosimilar Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada Senator Introduces Bill to Rid Switching Study Requirements for Interchangeability BioRationality: A Dr Sarfaraz Niazi Column—FDA Launches Biosimilar Regulatory Science Program AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?

  • S5 Ep11: What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

    27/11/2022 Duración: 19min

    Show notes: To read more about Amgen’s Biosimilar Trends Report, click here. To learn more about the Inflation Reduction Act’s impact on biosimilars, click here. To see more of Chad’s takeaways from older version of Amgen’s Biosimilar Trends Report, click here. To learn more about tender systems, click here. To check out the last episode of Not So Different, click here.

  • S5 Ep10: AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?

    13/11/2022 Duración: 19min

    This episode is made in conjunction with the third annual Global Biosimilars Week, a biosimilar awareness campaign hosted by the International Generic and Biosimilar Association (IGBA) from November 14 through November 18. The Center for Biosimilars is a proud media partner for Global Biosimilars Week and you can check all our social media pages to view our coverage of the event. To learn more about Global Biosimilars Week, click here. To learn more about BsUFA III, click here. To learn more about the Inflation Reduction Act, click here. To learn more about President Biden’s executive order, click here. To learn more about President Biden’s support for biotechnology, click here. To learn more about efforts to investigate pharmacy benefit managers, click here. To learn more about the FDA’s recent workshop, click here. To learn more about the FDA’s updated guidance on interchangeability, click here. To learn more about the approval of Cimerli, click here, and to learn more about the controversy surrounding it,

  • S5 Ep10: Biosimilars Policy Roundup for October 2022—Podcast Edition

    06/11/2022 Duración: 05min

    Show notes Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Policy Advocacy Organization Calls for Ontario to Switch Patients to Biosimilars BioRationality: a Dr Sarfaraz Niazi Column—The EMA Declares Biosimilars Interchangeable Biden Authorizes Update to the Biosimilar User Fee Act Through 2027 New Bill Aims to Remove Barriers to Interchangeable Biosimilars Amgen Report: Biosimilars Have Saved $21 Billion in 6 Years It’ll Take a Village: Collaborative Efforts Needed to Increase Ophthalmology Biosimilar Uptake Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy 

  • S5 Ep9: Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency

    16/10/2022 Duración: 13min

    Show notes:  To read more of Kathy’s thoughts on the practice perspective regarding biosimilars, click here. To learn more about automatic substitution policies, click here.  To learn more about some of the challenges clinicians could face next year as adalimumab biosimilars enter the market, click here. To learn more about prescription behaviors regarding biosimilars, click here. To listen to another podcast episode on a tool that can improve infusion center efficiency, click here. 

  • S5 Ep8: Biosimilars Oncology Roundup for September 2022—Podcast Edition

    02/10/2022 Duración: 04min

    Show notes FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar https://www.centerforbiosimilars.com/view/fda-approves-stimufend-the-us-sixth-pegfilgrastim-biosimilar  FDA Approves Celltrion Biosimilar for Avastin, Vegzelma https://www.centerforbiosimilars.com/view/fda-approves-celltrion-biosimilar-for-avastin-vegzelma Oncology, Ophthalmology Biosimilars Progress in Europe https://www.centerforbiosimilars.com/view/oncology-ophthalmology-biosimilars-progress-in-europe Biosimilars Check-In: Canada Approves Third Etanercept; Prestige Withdraws Trastuzumab Application https://www.centerforbiosimilars.com/view/biosimilars-check-in-canada-approves-third-etanercept-prestige-withdraws-trastuzumab-application Coherus Rep Shares Competition Strategy for Adalimumab, Pegfilgrastim Biosimilars https://www.centerforbiosimilars.com/view/coherus-rep-previews-interchangeable-ranibizumab-adalimumb-launches-on-pro-competitor?seriesVid=5 Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts h

  • S5 Ep7: How Heath Policy Can Impact Adoption for Adalimumab Biosimilars

    25/09/2022 Duración: 22min

    This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars. To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here. To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here. To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here. To listen to the other podcast in this series, “What Will Year 1 Look Like for Adalimumab Biosimilars?” click here.

  • S5 Ep6: What Will Year 1 Look Like for Adalimumab Biosimilars?

    11/09/2022 Duración: 22min

    This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars. To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here. To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here. To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here. To listen to the other podcast in this series, “What Will Year 1 Look Like for Adalimumab Biosimilars?” click here.

  • S5 Ep5: Biosimilars Regulatory Roundup for August 2022—Podcast Edition

    04/09/2022 Duración: 04min

    Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics https://www.centerforbiosimilars.com/view/opinion-impact-of-inflation-reduction-act-2022-addressing-critics Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition $35 Insulin Cap for Private Sector Blocked From Budget Reconciliation Bill https://www.centerforbiosimilars.com/view/-35-insulin-cap-for-private-sector-blocked-from-budget-reconciliation-bill European Commission Approves Second Lucentis Biosimilar https://www.centerforbiosimilars.com/view/european-commission-approves-second-lucentis-biosimilar FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab https://www.centerforbiosimilars.com/view/fda-approves-coherus-cimerli-as-interchangeable-biosimilar-to-ranibizumab FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar https://www.

  • S5 Ep4: Tools of the Trade: How McKesson’s Intrafusion Improves Infusion Center Efficiency, Biosimilar Utilization

    21/08/2022 Duración: 15min

    Show notes: To learn more about McKesson’s Intrafusion, click here. To learn more about biosimilar storage concerns, click here.

  • S5 Ep3: Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition

    07/08/2022 Duración: 04min

    Show notes Written version of the roundup Phase 3 denosumab trial results Alvotech’s pharmacokinetics trial for denosumab Poster from the American Society of Clinical Oncology’s annual meeting Phase 1 pertuzumab trial Rituximab studies from the European Hematology Association Congress 2022 Survey on preparing patients and providers for switching to a biosimilar

  • S5 Ep2: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market

    24/07/2022 Duración: 12min

    To learn more about the hype regarding adalimumab biosimilars in the US, click here. To see which biosimilars have been approved by the FDA, click here. To read more on PBMs and their influence on biosimilar uptake, click here. To read Manolis’ 2016 paper, click here.

página 3 de 8